dr-mignon-loh-md-104-1440x784-2x
dr-mignon-loh-md-104-320x320-2x

Mignon L. Loh

MD

Chief of Pediatric Hematology and Oncology
Pediatric hematologist-oncologist
Fan of cooking and hiking

Dr. Mignon Loh, chief of pediatric hematology and oncology, is a cancer specialist who focuses on caring for children with leukemia.

The mission of Loh's research is to bring new laboratory discoveries on pediatric leukemia into the clinic, to ensure that children with the condition receive the most appropriate therapies. Specifically, she investigates better ways to diagnose or treat the disease, as well as ways to predict how an individual patient’s illness will progress.

Loh earned her medical degree at Columbia University. She completed a residency in pediatrics at Boston Children's Hospital and a fellowship in pediatric hematology and oncology at Brigham and Women's Hospital. During her time in Boston, she served as an instructor at Harvard Medical School and as a research fellow at Brigham and Women's Hospital.

For the international research organization Children's Oncology Group, Loh chairs a committee on acute lymphoblastic leukemia (ALL) and is responsible for developing the clinical trial portfolio for newly diagnosed and relapsed patients with the condition. She supervises a highly productive committee and since July 2019 has opened three trials to investigate questions about new immunologic treatments for ALL in children, adolescents and young adults.

  • Education

    Columbia University, 1991

  • Residencies

    Boston Children's Hospital, Pediatrics, 1994

  • Fellowships

    Brigham and Women's Hospital, Pediatric Hematology and Oncology, 1998

  • Academic Title

    Professor

Where I see patients (2)

    Decorative Caduceus

    Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL...

    Power calculations are based on detecting an improvement in post consolidation DFS with the addition of InO to standard therapy for high risk (HR) B-acute lymphoblastic leukemia (ALL). All survival time analyses assume a Weibull d...

    Recruiting

    More about this study
    Decorative Caduceus

    Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philad...

    Will compare the DFS of standard risk Philadelphia chromosome (Ph+) acute lymphoblastic leukemia (ALL) patients treated continuous imatinib mesylate with high risk Children's Oncology Group (COG)-ALL chemotherapy backbone or more ...

    Recruiting

    More about this study
    Decorative Caduceus

    A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With...

    MRD negative Rem-2 be defined as Rem-2 (i.e., achievement of MRD < 1% blasts by flow cytometry and resolution of extramedullary disease (for CNS disease, requires CNS 1) ) and bone marrow with MRD < 0.01% by flow cytometry. MRD ne...

    Recruiting

    More about this study
    Decorative Caduceus

    A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chr...

    The RP2D is the maximum tolerated dose (MTD) or less.

    Recruiting

    More about this study
    Decorative Caduceus

    A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia

    Recruiting

    More about this study
    Decorative Caduceus

    Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or...

    The response rate will be estimated using the proportion of eligible/evaluable patients with CR/CRi response. A one-sided lower 95% Agresti-Coull confidence limit will be calculated.

    Recruiting

    More about this study
    See all clinical trials

    Stress-free visits

    Accommodations. Admissions. Procedure prep. Get the info you need for smoother hospital stays.

    Prepare for your child's stay

    Share